Once daily versus radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice


Once daily versus radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice

Glatzer, M.; Faivre-Finn, C.; de Ruysscher, D.; Widder, J.; van Houtte, P.; Troost, E. G. C.; Dahele, M.; Slotman, B.; Ramella, S.; Pöttgen, C.; Peeters, S.; Nestle, U.; Mcdonald, F.; Le Pechoux, C.; Dziadziuszko, R.; Belderbos, J.; Putora, P.

Background: In limited disease small cell lung cancer, the convert trial has demonstrated similar results with once-daily (QD) radiotherapy (66 Gy) and twice-daily (BID) radiotherapy (45 Gy). The selection among these regimes may be influenced by several factors. Methods: Thirteen European radiotherapy experts in SCLC as defined by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. The decision criteria were unified, the strategies were converted into decision trees and analysed for consensus and discrepancies. Results: Logistical reasons, performance status of the patient and dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimes was balanced among European experts, but there was a trend towards the BID regime for fit patients able to travel twice a day to the radiotherapy site. Conclusion: BID and QD radiotherapy are both accepted treatment options among experts and the decision may be influenced by pragmatic factors such as availability of transportation.

Permalink: https://www.hzdr.de/publications/Publ-31021
Publ.-Id: 31021